Dr. Reddy's Laboratories' CEO Discusses Q2 2012 Results -...

Dr. Reddy's Laboratories' CEO Discusses Q2 2012 Results - Earnings Call Transcript.

"... For this quarter, Lansoprazole, Fondaparinux and Omeprazole Magnesium OTC were the key products which drove the growth. We believe the initial market share update in Fondaparinux is at par of expectations, and we expect to ramp up our manufacturing volume and increase the market share gradually for the next coming months.

As we had mentioned in our earlier calls, we expect North America business to do even better in the second half of the year on the back of new customer orders and script work, scale-up in our business launches and other new launches and market share improvements. - Kallam Satish Reddy. "

Transcript here:

http://seekingalpha.com/article/302001-dr-reddy-s-laboratories-ceo-discusses-q2-2012-results-earnings-call-transcript